1334419-89-4

Upstream product

• 404827-77-6 ethyl 3-(3-(cyclopropanecarboxamido)-1H-indazol-6-yl)benzoate 
• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 1334419-88-3 N-(6-bromo-1H-indazol-3-yl)cyclopropanecarboxamide 
• 4334-87-6 [3-(ethoxycarbonyl)phenyl]boronic acid 

Downstream Products

• 1334419-59-8 3-(3-(cyclopropanecarboxamido)-1H-indazol-6-yl)-N-(3-(trifluoromethyl)phenyl)benzamide 
• 1334419-69-0 C₁₉H₁₈N₄O₂ 
• 1334419-65-6 C₂₇H₃₁N₅O₂ 
• 1334419-64-5 C₂₄H₂₇N₅O₃ 
• 1334419-63-4 C₂₉H₂₃F₃N₆O₂ 
• 1334419-76-9 C₃₂H₃₃F₃N₆O₂ 

Relevant academic research and scientific papers

An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit

Here we describe the synthesis and characterization of a number of 3-amino-1H-indazol-6-yl-benzamides that were designed to target the 'DFG-out' conformation of the kinase activation loop. Several compounds such as 4 and 11 exhibit single-digit nanomolar EC50s against FLT3, c-Kit and the gatekeeper T674M mutant of PDGFRα.

INDAZOLE COMPOUNDS AND THEIR USES

The present application relates to therapeutic organic compounds, compositions comprising an effective amount of a therapeutic organic compound; and methods for treating and preventing disease comprising administering and effective amount of a therapeutic organic compound to a subject in need thereof.